Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Pusch, S., Krausert, S., Fischer, V., Balss, J., Ott, M., Schrimpf, D., Capper, D., Sahm, F., Eisel, J., Beck, A.C., Jugold, M., Eichwald, V., Kaulfuss, S., Panknin, O., Rehwinkel, H., Zimmermann, K., Hillig, R.C., Guenther, J., Toschi, L., Neuhaus, R., Haegebart, A., Hess-Stumpp, H., Bauser, M., Wick, W., Unterberg, A., Herold-Mende, C., Platten, M., von Deimling, A.(2017) Acta Neuropathol 133: 629-644
- PubMed: 28124097 
- DOI: https://doi.org/10.1007/s00401-017-1677-y
- Primary Citation of Related Structures:  
5LGE - PubMed Abstract: 
Mutations in codon 132 of isocitrate dehydrogenase (IDH) 1 are frequent in diffuse glioma, acute myeloid leukemia, chondrosarcoma and intrahepatic cholangiocarcinoma. These mutations result in a neomorphic enzyme specificity which leads to a dramatic increase of intracellular D-2-hydroxyglutarate (2-HG) in tumor cells ...